Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

63.35 +2.58 (+4.25%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough ↗

September 01, 2025

Via Stocktwits

Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease ↗

August 30, 2025

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

Via Investor's Business Daily

Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy — Here's Where He's Investing Instead ↗

August 26, 2025

A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.

Via Benzinga

CYTK Earnings Jump 3,065% ↗

August 07, 2025

Via The Motley Fool

Topics Economy Intellectual Property

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

May 08, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

May 08, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

May 07, 2025

From Law Offices of Frank R. Cruz

Via Business Wire

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

May 02, 2025

From The Schall Law Firm

Via Business Wire

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months ↗

May 02, 2025

FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.

Via Benzinga

Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK

May 02, 2025

From DJS Law Group

Via Business Wire

Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 02, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

May 01, 2025

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 01, 2025

Via Benzinga

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday ↗

April 24, 2025

Via Benzinga

Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach ↗

April 21, 2025

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use

Via Benzinga

Which stocks are moving after the closing bell on Wednesday? ↗

April 16, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 16, 2025

Via Benzinga

Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday? ↗

April 15, 2025

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

Via Benzinga

Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 15, 2025

Via Benzinga

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It ↗

April 14, 2025

The companies are facing off with their heart drugs in a growing disease area.

Via Investor's Business Daily

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday ↗

April 02, 2025

Via Benzinga

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged ↗

April 02, 2025

Edgewise Therapeutics stock dropped, as Cytokinetics shares got a big boost early Wednesday.

Via Investor's Business Daily

Topics Bankruptcy

Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday ↗

March 21, 2025

Via Benzinga

MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 13, 2025

Via Benzinga

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

February 13, 2025

Via Benzinga

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

January 22, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

All News about Cytokinetics, Incorporated - Common Stock

Starting at $3.75/week.

Subscribe Today